GlassScriptPhysician profile
Jennifer M Jo
NPI 1063596120
$2,669.12
in general payments reported to CMS, 2019-2025
35 companies · $882 in 2025
The $882 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $154 · 2021: $168 · 2022: $16.00 · 2023: $302 · 2024: $714 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $492.13 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Abbvie INC. | $304.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $254.32 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $199.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $161.85 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.37 | 2019-2025 | Jardiance |
| Pfizer INC. | $127.65 | 2019-2025 | |
| Astellas Pharma US INC | $92.24 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $91.57 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $87.87 | 2023-2025 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $61.83 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $52.12 | 2019-2020 | |
| Glaxosmithkline, LLC. | $51.70 | 2024-2025 | Shingrix, Arexvy |
| Abiomed | $48.17 | 2024-2025 | Impella |
| Sumitomo Pharma America, INC. | $42.86 | 2024-2025 | Gemtesa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $39.44 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $37.82 | 2019 | |
| Abbott Laboratories | $36.38 | 2023-2025 | Freestyle Libre 3, Eterna |
| Dexcom, INC. | $33.54 | 2024-2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $32.26 | 2024 | Fluad, Flucelvax |
| Gilead Sciences, INC. | $28.24 | 2024 | |
| Antares Pharma, INC. | $26.24 | 2019 | |
| Sanofi Pasteur INC. | $25.52 | 2024 | |
| Merck Sharp & Dohme LLC | $23.06 | 2019 | |
| Hologic Sales and Service, LLC | $20.00 | 2025 | Aptima, Thinprep 2000 Processor |
| Tms Neurohealth Centers INC. | $19.47 | 2025 | Tms Neurohealth Centers INC. |
| Dermira, INC. | $16.39 | 2020 | |
| Dendreon Pharmaceuticals LLC | $16.16 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.85 | 2019 | |
| Sonex Health, INC. | $15.42 | 2025 | Sx-One Microknife |
| Esperion Therapeutics, INC. | $12.98 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.57 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.53 | 2019 | |
| Currax Pharmaceuticals LLC | $12.33 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Jo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.